MADISON, Wis.--(BUSINESS WIRE)--Roche NimbleGen Inc., a company of Roche Applied Science, and Affymetrix Inc. announced that they have expanded the terms of the license to a number of Affymetrix patents originally granted in October 2006. The expanded license now provides certain diagnostic rights for array-based DNA copy number analysis and array-based re-sequencing in addition to covering the manufacture, use and sale of nucleic acid microarrays and related products and services in the research field. Financial details of the expanded license were not disclosed.
Roche NimbleGen is a leading innovator, manufacturer and supplier of a proprietary suite of DNA microarrays, consumables, instruments and services. Roche NimbleGen uniquely produces high-density arrays of long oligo probes that provide greater information content and higher data quality necessary for studying the full diversity of genomic and epigenomic variation. The improved performance is made possible by Roche NimbleGen’s proprietary Maskless Array Synthesis (MAS) technology, which uses digital light processing and rapid, high-yield photochemistry to synthesize long oligo, high-density DNA microarrays with extreme flexibility. For more information about Roche NimbleGen, please visit the company’s website at www.nimblegen.com.
About Roche
Headquartered in Basel, Switzerland, Roche is one of the world’s leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As the world’s biggest biotech company and an innovator of products and services for the early detection, prevention, diagnosis and treatment of diseases, the Group contributes on a broad range of fronts to improving people’s health and quality of life. Roche is the world leader in in-vitro diagnostics and drugs for cancer and transplantation, and is a market leader in virology. It is also active in other major therapeutic areas such as autoimmune diseases, inflammatory and metabolic disorders and diseases of the central nervous system. In 2007 sales by the Pharmaceuticals Division totalled 36.8 billion Swiss francs, and the Diagnostics Division posted sales of 9.3 billion francs. Roche has R&D agreements and strategic alliances with numerous partners, including majority ownership interests in Genentech and Chugai, and invested over 8 billion Swiss francs in R&D in 2007. Worldwide, the Group employs about 79,000 people. Additional information is available on the Internet at www.roche.com.
NimbleGen is a trademark of Roche NimbleGen, Inc.
Other brands or product names are trademarks of their respective holders.
Contact:
Roche NimbleGen Joleen Rau, +1-608-218-7623 jrau@nimblegen.com or
Roche Diagnostics GmbH Dr. Burkhard Ziebolz, +49-8856-60-4830 burkhard.ziebolz@roche.com
Source: Roche NimbleGen
